52 results about "Arthritis gout" patented technology

Novel compounds of the structural formula (I), and the pharmaceutically acceptable salts thereof, are inhibitors of NLRP3 and may be useful in the treatment, prevention, management, amelioration, control and suppression of diseases mediated by NLPR3. The compounds of structural formula I may be useful in the treatment, prevention or management of diseases, disorders and conditions mediated by NLRP3 such as, but not limited to, gout, pseudogout, CAPS, NASH fibrosis, heart failure, idiophathic pericarditis, atopic dermatitis, inflammatory bowel disease, Alzheimer's Disease, Parkinson's Disease and traumatic brain injury.

The invention relates to a gouty arthritis patient pain management method and system based on an MDT management mode, and the method comprises the steps: automatically collecting the multivariate clinical data of a patient through integrating an existing information system of a hospital, carrying out the cleaning, standardization and structural processing through a special data preprocessing module, and carrying out the cleaning, standardization and structural processing. A machine learning prediction model trained by historical data is utilized to automatically generate a personalized MDT nursing plan, tasks are intelligently distributed to corresponding team members by means of a workflow engine, the execution condition is continuously monitored in the intervention process, and the nursing scheme is dynamically adjusted based on clinical data and prediction results which are periodically updated. And a complete'monitoring-prediction-intervention-reevaluation 'closed-loop management process is formed. The problems that a traditional MDT mode depends on manpower, efficiency is low, and decision-making lacks data support are effectively solved, and the accuracy, the collaboration and the continuity of pain management and wound surface nursing of the gouty calculus combined infection patient are improved.

Novel compounds of Formula (I), and the pharmaceutically acceptable salts thereof, are inhibitors of NLRP3 and may be useful in the treatment, prevention, management, amelioration, control and suppression of diseases mediated by NLPR3. The compounds of the present invention may be useful in the treatment, prevention or management of diseases, disorders and conditions mediated by NLRP3 such as, but not limited to, obesity, gout, pseudogout, CAPS, NASH, MASH, fibrosis, heart failure, idiopathic pericarditis, atopic dermatitis, inflammatory bowel disease, Alzheimer's Disease, Parkinson's Disease, dementia with Lewy bodies (DLB), and traumatic brain injury.

The present invention relates to the technical field of Chinese medicine and preparation method for treating gouty arthritis, a pharmaceutical composition for treating gouty arthritis and its preparation method and application, the pharmaceutical composition, the medicinal materials include aconite, fenugreek, cassia twig, Poria, Rhizoma Smilacis Glabrae, Caulis Trachelospermi and Codonopsis Pilosula of specific compatibility, and the pharmaceutical composition is prepared by reflux decoction. The pharmaceutical composition of the present invention has a precise compatibility of each medicinal flavor, and plays a synergistic effect together, has the effects of warming yang and removing dampness, promoting qi, unblocking channels, reducing swelling, dispersing knots and relieving pain, and for gout cold-damp syndrome, can treat cold-damp accumulation, qi stagnation and blood stasis syndromes, tendon and bone pain, hand and foot paralysis and pain, foot and knee swelling and pain, qi stagnation and blood stasis, nodule swelling and pain, nodule immobility, etc., has a good therapeutic effect on cold-dampness arthritis, and the recurrence rate is low. At the same time, the pharmaceutical composition of the present invention has few raw materials, is easy to prepare, convenient to use, has a definite efficacy, stable medicinal properties, and good patient compliance, and has a good application prospect.

Novel compounds of the structural formula (I), and pharmaceutically acceptable salts, hydrates and solvates thereof, are inhibitors of NLRP3 and may be useful in the treatment, prevention, management, amelioration, control and suppression of diseases mediated by NLPR3. The compounds of structural formula I may be useful in the treatment, prevention or management of diseases, disorders and conditions mediated by NLRP3 such as, but not limited to, gout, pseudogout, CAPS, NASH fibrosis, heart failure, idiopathic pericarditis, atopic dermatitis, inflammatory bowel disease, Alzheimer's Disease, Parkinson's Disease and traumatic brain injury.

The invention belongs to the technical field of application of traditional Chinese medicines, and specifically relates to an application of an Amomum villosum extract in preparing a UA-lowering and anti-gouty arthritis drug. The Amomum villosum extract is extracted to obtain the Amomum villosum extract. A hyperuricemia mouse model and a gouty arthritis mouse model are established, and the results show that the Amomum villosum ethanol extract reduces the UA level by synergistically reducing excessive UA generation and promoting UA excretion, and comprehensively exerts an anti-gout effect by inhibiting the release of inflammatory factors such as IL-6, TNF-α and IL-1β, and has the characteristics of better drug efficacy and better drug safety. Therefore, the Amomum villosum ethanol extract can be applied to drugs and health foods for gout patients, and has better development and utilization value as well as huge social and economic benefits.

1. The name of this design product: Physiotherapy device. 2. Purpose of this design product: It is a medical device used for the rehabilitation of gout. 3. The key point of the design of this product lies in its shape. 4. The picture or photo that best illustrates the design points: three-dimensional picture.

The present application relates to novel substituted indazoles, to processes for preparation thereof, to the use thereof alone or in combinations for treatment and / or prophylaxis of diseases, and to the use thereof for production of medicaments for treatment and / or prophylaxis of diseases, especially for treatment and / or prophylaxis of endometriosis and endometriosis-associated pain and other endometriosis-associated symptoms such as dysmenorrhoea, dyspareunia, dysuria and dyschezia, of lymphoma, rheumatoid arthritis, spondyloarthritis (especially psoriatic spondyloarthritis and Bekhterev's disease), lupus erythematosus, multiple sclerosis, macular degeneration, COPD, gout, fatty liver disorders, insulin resistance, neoplastic disorders and psoriasis.

The invention relates to the technical field of effervescent tablets, and particularly discloses a medicinal and edible composite effervescent tablet for treating gout as well as a preparation method and application of the medicinal and edible composite effervescent tablet. The medicinal and edible composite effervescent tablets are prepared from the following raw materials: 10-30 parts of a honeysuckle extract, 10-30 parts of a Chinese olive extract, 10-30 parts of a gardenia extract, 10-30 parts of a dandelion extract, 3-8 parts of a disintegrating agent, 5-10 parts of a sweetening agent, 1-5 parts of a filling agent, 2-5 parts of a wetting agent, 15-30 parts of an acid source and 25-40 parts of an alkali source. According to the prepared medicinal and edible composite effervescent tablet, traditional Chinese medicine components with gout treatment effects are organically combined with nutrients, and a safe and effective new dietary therapy choice is provided for patients.

The present invention can provide a composition for treating gout or a method for treating gout, the composition containing a nano-drug in which a cyclodextrin moiety is conjugated to an amino group of a polymer, wherein a visible or near-infrared fluorophore is further conjugated to a carboxyl group of the polymer or the nano-drug further contains at least one gout therapeutic agent, which forms a complex together with the cyclodextrin moiety.

The invention belongs to the technical field of biological medicines, and particularly relates to a benzo [5, 6] spiroacetal lactone NLRP3 inflammasome inhibitor as well as a synthesis method and application of the benzo [5, 6] spiroacetal lactone NLRP3 inflammasome inhibitor. The benzo [5, 6] spiroacetal lactone compound with a structure of a general formula (I) is designed and synthesized from a dominant skeleton of a marine natural product, the benzo [5, 6] spiroacetal lactone compound shows remarkable activity of inhibiting NLRP3 inflammasomes, and the IC50 value of part of the compound is hundreds of nanomoles, so that the compound has a wide application prospect. The result in an in-vitro experiment is equivalent to the inhibition effect of reported compounds glibenclamide and JC124 of the same type. Besides, in an in-vivo anti-inflammatory experiment, the compounds S6 and S13 can efficiently inhibit activation of the NLRP3 inflammasome and reduce release of proinflammatory factors such as IL-1beta and IL-18, and can be used for preparing drugs for treating diseases related to abnormal activation of the NLRP3 inflammasome, such as gout, rheumatoid arthritis, type 2 diabetes mellitus, neurodegenerative diseases and atherosclerosis. # imgabs0 #

This invention relates to pharmaceutical compositions and uses of NAMPT as a therapeutic target for gout; specifically, to the use of NAMPT inhibitors to treat acute gouty arthritis in subjects.

The invention relates to a pharmaceutical composition taking NAMPT as a gout treatment target and application. In particular, the invention relates to the treatment of acute gouty arthritis diseases in a subject using a NAMPT inhibitor.

The invention belongs to the technical field of medicines, and particularly relates to application of thiazolidinone compounds or pharmaceutically acceptable salts thereof in preparation of CRM1 protein inhibitors, and the thiazolidinone compounds have the following structure. Preferably, the CRM1 protein inhibitor is a medicine for treating chronic inflammatory diseases, and the chronic inflammatory diseases are inflammatory bowel diseases, rheumatic arthritis, gout, atherosclerosis or type II diabetes mellitus. The thiazolidone compound has high inhibitory activity on CRM1 protein, significantly reduces the expression quantity of key inflammatory factors and nitric oxide in an inflammatory cell model, has an anti-inflammatory effect superior to that of a clinical first-line anti-inflammatory drug mesalazine, has small side effects, is suitable for clinical application, and has broad application prospects. Therefore, the method has huge potential market space and economic benefits. # imgabs0 #

This application relates to the technical field of traditional Chinese medicine, and provides a traditional Chinese medicine composition and a preparation method thereof. The raw materials of the traditional Chinese medicine composition include polygonum cuspidatum, dioscorea septemloba, cyathula officinalis, millettia reticulata, notoginseng powder, and smilax glabra. This application also provides an oral preparation, which is prepared from the above traditional Chinese medicine composition and pharmaceutically acceptable excipients according to the preparation process. This application also provides the use of the above traditional Chinese medicine composition or the above oral preparation in the preparation of a drug having at least one of the effects of clearing heat, resolving dampness, expelling pathogenic factors, tonifying the liver and kidney, and strengthening the bones and muscles, the preparation of a drug for treating hyperuricemia, or the preparation of a drug for treating at least one of gout, gouty nephropathy, and gouty arthritis. The traditional Chinese medicine composition of this application has the effect of treating hyperuricemia and its complications, has definite curative effect and small side effects, can be used for the treatment of gout, gouty nephropathy, and gouty arthritis, and provides a new drug option for clinical practice.

The invention relates to a method for extracting components for treating gout in a sunflower disk, which improves the yield of a solid extract by improving the macroporous resin elution step, and in the extracted solid extract, the contents of effective components such as rutin, caffeic acid and 6-methylcoumarin for treating gout are obviously increased.

This invention belongs to the field of biomedical technology, specifically relating to an ointment and its application. The toad oil used in this invention differs significantly in composition from toad venom, and its ointment is effective for various acute and chronic pain conditions. Animal experiments have confirmed that the toad oil ointment significantly reduces the frequency and delays the onset of acetic acid-induced writhing responses, demonstrating a clear analgesic effect. Clinical studies have shown that this ointment is rapidly effective and has a definite therapeutic effect on acute gout attacks, postherpetic neuralgia, and arthritis-related pain and swelling. The formulation effectively improves drug retention and user comfort, and no skin irritation has been observed. This development achieves comprehensive utilization of toad resources, providing an example for the sustainable development of traditional Chinese medicine and the efficient utilization of biological resources.

The invention provides a microneedle administration method for treating gout, and relates to the field of gout administration, and the microneedle administration method comprises the following steps: S100, preparing a needle tip gel solution: mixing a gout treatment drug with hyaluronic acid, and stirring until the gout treatment drug and hyaluronic acid are completely dissolved to form a drug-loaded needle tip gel solution; s200, preparing a backing gel solution: dissolving hyaluronic acid in an aqueous solvent, and stirring until the hyaluronic acid is completely dissolved to form the backing gel solution. S300, injecting the needle tip gel solution into a needle hole of a microneedle mold, sequentially carrying out vacuum drying and centrifugal treatment to enable the needle hole to be fully filled with the solution, and drying the needle tip for 150 minutes; s400, the surface of a mold is covered with the backing gel solution, vacuum drying is conducted, and a backing layer is formed; and S500, demolding to obtain the drug-loaded microneedle patch, and attaching the drug-loaded microneedle patch to the skin of a patient to deliver a drug. The medicine is directly delivered to the corium layer through the microneedle, the liver first-pass effect and gastrointestinal tract degradation caused by oral administration are avoided, the medicine is released after microneedle puncture, and the medicine is suitable for rapid analgesia in the gout acute attack period, reduction of whole body exposure through local administration, reduction of the gastrointestinal ulcer occurrence rate of NSAIDs medicines and reduction of side effects. The length of the microneedle is 200-800 micrometers, the microneedle only penetrates through the cuticle, nerve endings are prevented from being damaged, the patch is packaged in a sterile aluminum-plastic bubble cap, a patient can attach the patch by himself / herself, and the requirement for frequently seeing a doctor is reduced.

This invention discloses a multimodal risk stratification system for gout patients based on prompting engineering, belonging to the field of medical informatics and AI-assisted chronic disease management technology. The system acquires and integrates structured diagnostic and treatment data and unstructured medical record text of gout patients through a construction unit, generating a patient time-series diagnostic and treatment dataset; a parsing unit extracts key semantic tags based on a gout diagnostic and treatment knowledge base and a dynamic prompting template-driven large language model; a calibration unit performs directional conflict verification between semantic tags and laboratory indicators, diagnostic codes, medication records, and adjacent medical records, generating confidence correction values; a stratification unit performs time axis alignment and weighted coding to obtain risk stratification results; and a feedback unit generates explanatory information and risk evolution records, and updates the prompting template in reverse. This system can improve the accuracy, interpretability, and dynamic adaptability of risk stratification for gout patients.

The invention relates to the technical field of prediction models, and particularly discloses a gout recurrence prediction model and a construction method thereof. Clinical index data and the standardized protein expression level of immune-related molecules in plasma are used for constructing the gout recurrence prediction model, the gout recurrence prediction model obtained through the method has the stable prediction capacity, and MMP1 achieves the very high AUC value and accuracy and the lowest Brier score.

The present disclosure relates to nucleic acid sequences encoding uricase, polynucleotides, expression cassettes, and delivery vectors comprising the nucleic acid sequences, and methods for delivering or administering the nucleic acid sequences to treat gout, chronic refractory gout, and / or Harrison syndrome.

The invention relates to a Jinhuang powder drug-loaded microneedle for improving gouty arthritis and a preparation method thereof. The preparation method comprises the following steps: step 1, researching the action mechanism of the Jinhuang powder for treating the gouty arthritis; 2, according to the research result, increasing the proportion of cortex phellodendri, cortex magnoliae officinalis and liquorice in the original golden-huang powder prescription, and reducing the proportion of other medicinal materials to obtain a new golden-huang powder prescription; and step 3, preparing the Jinhuang powder drug-loaded microneedle on the basis of the new prescription of the Jinhuang powder. A golden yellow powder medicinal material is loaded through a microneedle, painless drug delivery of the microneedle is utilized, the delivery efficiency is higher than that of traditional transdermal drug delivery, good biocompatibility is achieved for delivery of protein and nucleic acid macromolecular drugs, the drug delivery efficiency can be improved, the drugs are delivered to specific parts in a targeted mode, adverse reactions of the drugs are reduced, and the utilization rate of the drugs is increased; the proportion of the golden cypress, the mangnolia officinalis and the liquorice in an original golden-yellow powder prescription is increased, and the treatment effect of the golden-yellow powder drug-loaded microelement on gouty arthritis is further enhanced.

1. The name of the product of this design: packaging bag (bones and tendons gout patch). 2. Purpose of this design product: used for packaging products. 3. The design key point of this appearance design product lies in the combination of shape and pattern. 4. The picture or photo that best illustrates the key points of the design: main view. 5. This design product is a flat product and other views are omitted.

The present disclosure features chemical entities (e.g., compounds or pharmaceutically acceptable salts thereof) that degrade and / or otherwise modulate (e.g., inhibit) NIMA-related kinase 7 (NEK7). The chemical entities are useful, for example, in treating subjects having one or more conditions or diseases associated with NLRP3 inflammasome activation (e.g., human subjects). The conditions or diseases include, but are not limited to, autoinflammatory and autoimmune conditions (e.g., gout, inflammatory bowel disease, rheumatoid arthritis, multiple sclerosis), neurodegenerative diseases (e.g., Alzheimer's disease, Parkinson's disease), cardiovascular and metabolic conditions (e.g., pericarditis, atherosclerosis, type 2 diabetes mellitus, diabetes mellitus, diabetes mellitus, diabetes mellitus, diabetes mellitus, diabetes mellitus, diabetes mellitus, diabetes mellitus, and the like). ), fibrotic disorders (e.g., interstitial lung disease, chronic kidney disease), hematological disorders (e.g., inflammatory anemia), and ocular disorders (e.g., macular degeneration). In embodiments, although not desired to be constrained theoretically, the chemical entities described herein are believed to directly target (e.g., bind directly) NEK7, thereby altering (e.g., attenuating) the inflammatory response modulated by the NLRP3 inflammasome. The disclosure also features compositions containing the entities as well as methods of using and making the entities.

The # imgabs0 # provides a polymorphic substance of a GLP-1R agonist compound I as well as a preparation method and application of the polymorphic substance. Compared with the free state of the compound I, the polymorphic substance has higher stability and better processability; and the compound is more suitable for preparing medicines for preventing or treating diseases related to GLP-1R targets and signal channels thereof, such as type 2 diabetes mellitus, prediabetes mellitus, obesity, non-alcoholic fatty liver diseases, non-alcoholic steatohepatitis, nephropathy, gout, hyperhematuria, cardiovascular diseases and the like.

This invention provides the use of saikosaponin B2 in drug preparation, belonging to the field of natural medicine technology. This invention discovers that saikosaponin B2 has a significant inhibitory effect on NLRP3 inflammasome activation, and can be used to prepare NLRP3 inflammasome inhibitors, which can be used to prepare drugs for treating diseases related to NLRP3 inflammasomes (including gout and gouty arthritis), showing broad application prospects.

The application provides a chlorogenic acid amide derivative, a preparation method and application thereof. The chlorogenic acid amide derivative has a structure shown in general formula I, the active carboxylic acid part in the chlorogenic acid structure is chemically modified, different alkyl / aromatic amine groups and the like are connected, and the anti-inflammatory activity of the chlorogenic acid derivative is enhanced. Meanwhile, in order to improve the fat solubility of the chlorogenic acid derivative, the phenolic hydroxyl and alcoholic hydroxyl parts and the like in the structure are protected by etherification or acylation, and the fat solubility of the chlorogenic acid derivative is improved. The chlorogenic acid amide derivative has good anti-inflammatory activity in an acute inflammatory cell model in vitro and an acute gout rat model, and is an anti-inflammatory preparation with good development potential. The synthesis method of the chlorogenic acid amide derivative is simple and efficient, and compared with original drugs, has the characteristics of increasing fat solubility and stability, improving absorption performance, improving drug efficacy and reducing toxicity and the like.

Provided herein are formulations for topical and / or transdermal administration, and methods of using these formulations for the treatment of proliferative diseases related to cancer such as cancers and related conditions, and solid tumors. Also provided are formulations for topical and / or transdermal administration, and methods of using these formulations for melasma, gout, skin disorders, and other diseases and disorders described herein as well as methods for modulating the pH (e.g. raising) of a tissue or microenvironment proximal to a tumor, modulating pH, or improving the effectiveness of know chemotherapeutic agents, immunotherapy and the like for the prevention, treatment of cancers and related conditions described herein.

The invention provides a method for analyzing the action mechanism of wind-dispelling five-herb decoction for treating gout based on network pharmacology and molecular docking and application, and relates to the technical field of traditional Chinese medicine information analysis, the method comprises the following steps: acquiring a common target spot of a drug target spot of the wind-dispelling five-herb decoction and a gout disease target spot; the wind-dispelling five-herb decoction comprises lysimachia christinae hance, oldenlandia diffusa, lalang grass rhizome, plantain herb Constructing a protein interaction network based on the common target; screening core targets in the protein interaction network, and identifying core active components of the Chinese herbal medicine prescription; performing pathway enrichment analysis and function enrichment analysis on the common target spot to determine a drug action mechanism; and verifying the interaction strength of the core active component and the core target spot through molecular docking. By directly calling a plurality of biological databases and integrating molecular docking verification, the analysis process is simplified, and the mechanism that the wind-dispelling five-herb decoction acts on key targets and signal pathways through core active components to treat gout is accurately disclosed.